Entrada Therapeutics, Inc. (TRDA) Misses Q4 EPS by 12c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q4 EPS of ($0.29), $0.12 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $41.85 million versus the consensus estimate of $23.7 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c